| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025508.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025508.txt","company":"Spyre Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025508.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_6f10e8d801423cb0","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025508.txt","content_type":"text/plain","enriched_at":"2026-04-17T08:10:28.956027+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"syre-20260414","final_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025508.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025508.txt","source_event_id":"evt_320cd5d359b3","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"fa87d1581fb3fd95","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-13","2026-04-14","2026-04-16","2026-04-17"],"entities":[{"asset_class":"equity","name":"Spyre Therapeutics, Inc.","relevance":"high","symbol":"SYRE","type":"issuer"},{"asset_class":"equity","name":"Jefferies LLC","relevance":"medium","symbol":"","type":"underwriter_representative"},{"asset_class":"equity","name":"Goldman Sachs & Co. LLC","relevance":"medium","symbol":"","type":"underwriter_representative"},{"asset_class":"equity","name":"Evercore Group L.L.C.","relevance":"medium","symbol":"","type":"underwriter_representative"},{"asset_class":"equity","name":"Guggenheim Securities, LLC","relevance":"medium","symbol":"","type":"underwriter_representative"}],"event_type":"listing","information_gaps":["The specific 8-K Item(s) and any additional 8-K disclosures beyond the underwriting agreement are not provided in the cleaned text.","The offering price, gross proceeds, net proceeds, and any underwriting discount/commission are not included in the provided excerpt.","The final prospectus supplement details (e.g., final terms) are not shown; only definitions and references to preliminary materials are included.","The \u201cwhat changed vs prior known state\u201d cannot be determined from the provided text alone because no prior state or earlier filing context is included."],"key_facts":["Form 8-K filed by Spyre Therapeutics, Inc. (SYRE) is referenced with an underwriting agreement dated April 14, 2026.","The company proposes to issue and sell an aggregate of 6,500,000 shares of common stock (firm shares) at par value $0.0001 per share.","The underwriters are granted an option to purchase up to an additional 975,000 shares (optional shares).","Firm shares and optional shares are collectively referred to as the offered shares.","Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC are named as representatives of the underwriters.","The company prepared and filed a shelf registration statement on Form S-3, File No. 333-293600, including a base prospectus, to be used for the offering.","The text references a preliminary prospectus supplement dated April 13, 2026 and defines an \u201cApplicable Time\u201d of 5:40 p.m. (New York City time) on April 14, 2026."],"numeric_claims":[{"label":"Firm shares","value":"6,500,000"},{"label":"Optional shares (option size)","value":"975,000"},{"label":"Common stock par value","value":"$0.0001"},{"label":"Applicable time (NYC)","value":"5:40 p.m. on April 14, 2026"}],"primary_claim":"Spyre Therapeutics, Inc. filed a Form 8-K containing an underwriting agreement for an offering of 6,500,000 firm shares of common stock plus an option for up to 975,000 optional shares.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Spyre Therapeutics, Inc. filed an 8-K that includes an underwriting agreement dated April 14, 2026 for a proposed common stock offering. The agreement covers 6,500,000 firm shares and an option for up to 975,000 additional shares.","topics":["SEC filing","Form 8-K","underwriting agreement","common stock offering","shelf registration statement","Form S-3","equity issuance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Spyre Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"SYRE","tickers":["SYRE"],"title":"SYRE filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1636282/0001628280-26-025508.txt"}... |